跳至主要内容
临床试验/NCT07222423
NCT07222423已完成不适用

Epidemiology and Hospital Management of Patients With PROS in France: a PMSI Study

Novartis Pharmaceuticals1 个研究点 分布在 1 个国家目标入组 3,605 人开始时间: 2024年1月15日最近更新:

试验速览

阶段
不适用
状态
已完成
入组人数
3,605
试验地点
1
主要终点
Yearly Prevalence Rate

研究概览

简要总结

The purpose of this study was to estimate the incidence and prevalence of a group of genetic disorders known as PIK3CA-Related Overgrowth Spectrum (PROS) in France. Additionally, the study aimed to characterize patients, disease management, and costs associated with PROS. This study used data from the French National Hospitals Database, Programme de Médicalisation des Systèmes d'Information (PMSI). The study period was from January 2015 to December 2022.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Yearly Prevalence Rate

时间窗: Up to approximately 6 years

Yearly prevalence rate was calculated by dividing the number of identified patients with PROS by the total French population during the inclusion period. The inclusion period was from January 2017 to December 2022.

Yearly Incidence Rate

时间窗: Up to approximately 6 years

Yearly incidence rate was calculated by dividing the number of PROS newly diagnosed cases during the inclusion period (incident cases) by the total French population during the inclusion period. The inclusion period was from January 2017 to December 2022.

次要结局

  • Number of Patients by Patient Characteristics(Baseline)
  • Number of Comorbidities per Patient(Baseline)
  • Number of Patients by PROS Diagnosis(Baseline)
  • Average Length of Stay of Hospitalization(Baseline)
  • Number of Patients by Type of PROS-related Technical Procedures(Baseline)
  • Number of Patients by Type of Hospitalization(Baseline)
  • Number of Patients by Hospitalization Severity(Baseline)
  • Average Duration of Follow-up(Up to approximately 6 years)
  • Number of All-cause Hospitalizations During the Follow-up Period(Up to approximately 6 years)
  • Number of PROS-related Hospitalizations by Year of Follow-up(Up to approximately 6 years)
  • Number of PROS-related Hospitalizations During the Follow-up Period(Up to approximately 6 years)
  • Number of Patients With PROS-related Hospitalization During the Follow-up Period by Type of Hospitalization and Age Range(Up to approximately 6 years)
  • Average Length of Stay of PROS-related Inpatient Hospitalization During the Follow-up Period(Up to approximately 6 years)
  • Number of PROS-related Hospitalizations During the Follow-up Period by Level of Severity(Up to approximately 6 years)
  • Number of All-cause External Technical Procedures and Visits During the Follow-up Period(Up to approximately 6 years)
  • Number of Patients With at Least one All-cause External Technical Procedure and Visit During the Follow-up Period(Up to approximately 6 years)
  • Number of External Technical Procedures and Visits of Interest During the Follow-up Period(Up to approximately 6 years)
  • Number of Patients With an External Technical Procedure and Visit of Interest During the Follow-up Period(Up to approximately 6 years)
  • Number of External Technical Procedures and Visits by Specialty of the Performing Healthcare Professional During the Follow-up Period(Up to approximately 6 years)
  • Number of Emergency Room Visits not Followed by Hospitalization During the Follow-up Period(Up to approximately 6 years)
  • Number of Patients With at Least one Emergency Room Visit not Followed by Hospitalization During the Follow-up Period(Up to approximately 6 years)
  • Healthcare Resource Consumption Rate Per Patient-Year (PPY) During the Follow-up Period(Up to approximately 6 years)
  • Healthcare Costs PPY During the Follow-up Period(Up to approximately 6 years)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
不适用
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06747572Vertex Pharmaceuticals Incorporated401
尚未招募
不适用
Evaluation Of Details Of Patients Less Than 40 Years Of Age With Raised Pressure In The Eye
CTRI/2018/12/016529Dr Parab Aditi Pradeep384
已完成
不适用
Diagnostic and Screening Study of Genetic DisordersTay-Sachs DiseasePorphyria, ErythropoieticLeukodystrophy, Globoid CellMetabolism, Inborn Errors
NCT00006057National Center for Research Resources (NCRR)50
招募中
不适用
Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer SyndromesRenal Tumor HistologyKidney CancerFamilial Renal CancerHLRCCVHL SyndromeBAP1 Tumor Predisposition SyndromeFLCN Gene MutationALK Gene MutationRenal Cell CarcinomaFH Gene MutationBirt-Hogg-Dube SyndromeMET Gene MutationCutaneous Leiomyomata With Uterine LeiomyomataCutaneous Leiomyoma
NCT05534854RenJi Hospital500
已完成
不适用
Clinical Characteristics and Etiology of Infectious Optic Neuritis in ThailandDemographic data, clinical features, laboratory investigation, imaging study, clinical outcomes, etiology and associated factors to poor visual outcome of patients with infectious optic neuritis.infectious optic neuritis, parainfectious optic neuritis, demographic, clinical, investigation, treatment, imaging, clinical outcome, etiology, risk factor
TCTR20211115001Chulalongkorn University20
A Study of the Epidemiology and Hospital Management... | 临床试验